Henry Schein (NASDAQ:HSIC) Releases Q4 2024 Earnings Guidance

Henry Schein (NASDAQ:HSIC) issued an update on its fourth quarter 2024 earnings guidance on Wednesday morning. The company provided EPS guidance of 1.190-1.190 for the period, compared to the consensus EPS estimate of 1.230. The company issued revenue guidance of $3.2 billion-$3.2 billion, compared to the consensus revenue estimate of $3.3 billion. Henry Schein also updated its FY 2024 guidance to 4.740-4.740 EPS.

Henry Schein Price Performance

Shares of NASDAQ HSIC traded up $4.62 during mid-day trading on Wednesday, hitting $80.72. 610,562 shares of the stock traded hands, compared to its average volume of 1,010,598. The company has a market cap of $10.06 billion, a PE ratio of 33.26, a price-to-earnings-growth ratio of 2.04 and a beta of 0.89. Henry Schein has a twelve month low of $63.67 and a twelve month high of $82.63. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.42 and a quick ratio of 0.82. The firm has a 50 day simple moving average of $73.07 and a two-hundred day simple moving average of $71.21.

Henry Schein (NASDAQ:HSIC) last released its quarterly earnings results on Tuesday, November 5th. The company reported $1.22 earnings per share for the quarter, topping the consensus estimate of $1.17 by $0.05. The company had revenue of $3.17 billion for the quarter, compared to analysts’ expectations of $3.24 billion. Henry Schein had a return on equity of 12.90% and a net margin of 2.51%. The business’s quarterly revenue was up .4% compared to the same quarter last year. During the same period in the previous year, the business posted $1.32 earnings per share. As a group, equities research analysts forecast that Henry Schein will post 4.78 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on HSIC. Barrington Research reissued an “outperform” rating and issued a $82.00 price objective on shares of Henry Schein in a research note on Wednesday, November 6th. Evercore ISI raised their price objective on Henry Schein from $70.00 to $74.00 and gave the stock an “in-line” rating in a research report on Tuesday, October 8th. StockNews.com raised shares of Henry Schein from a “sell” rating to a “hold” rating in a research report on Thursday, November 7th. Bank of America upgraded shares of Henry Schein from an “underperform” rating to a “buy” rating and boosted their price target for the stock from $69.00 to $84.00 in a research report on Monday, January 6th. Finally, Jefferies Financial Group lifted their target price on shares of Henry Schein from $77.00 to $80.00 and gave the stock a “hold” rating in a research note on Thursday, January 23rd. Seven equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $79.30.

Insider Activity

In other Henry Schein news, COO Michael S. Ettinger sold 12,240 shares of the firm’s stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $75.00, for a total value of $918,000.00. Following the completion of the sale, the chief operating officer now owns 87,706 shares of the company’s stock, valued at approximately $6,577,950. This trade represents a 12.25 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 1.14% of the company’s stock.

Henry Schein Company Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.